IRVINE, Calif., Oct. 31, 2012 /PRNewswire/ -- Kennedy Health System, encompassing three acute care New Jersey hospitals on the cutting edge of new technology and medical procedures, today renewed the health system's long-standing contract and commitment to Masimo SET® as its pulse oximetry standard-of-care. Kennedy Health System signed another five-year contract with Masimo for SET® pulse oximetry and added rainbow® Pulse CO-Oximetry for advanced, noninvasive patient monitoring.
Kennedy Health System standardized on Masimo SET® pulse oximetry technology for Measure-Through Motion and Low Perfusion SpO2, pulse rate, and perfusion index measurements more than 10 years ago. Masimo SET® virtually eliminates false alarms1 and increases a clinician's ability to detect life-threatening events.2 More than 100 independent clinical studies have confirmed that Masimo SET® technology allows clinicians to accurately monitor blood oxygen saturation in the most challenging conditions establishing the technology as an industry-leading pulse oximetry that substantially contributes to improved patient outcomes.
Today, the health system is expanding its relationship with Masimo and deploying two new Masimo rainbow® SET® Pulse CO-Oximetry measurements: noninvasive total hemoglobin (SpHb®) and Pleth Variability Index (PVI®). Masimo SpHb enables clinicians to measure hemoglobin without a painful needle stick or time-consuming blood lab analysis,3 while PVI helps clinicians to noninvasively and continuously assess the fluid status of patients without invasive procedures.4
Masimo rainbow® SET® technology has been shown to have the highest pulse oximetry specificity (lowest rate of false alarms) and sensitivity (highest true alarm detection),2 as well as noninvasive patient monitoring solutions that allow clinicians to measure multiple blood constituents including: oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), acoustic respiration rate (RRa), and perfusion index (PI) in addition to the Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), and pulse rate (PR).
(1) Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers".J Clin Anesth. 2012 Aug;24(5):385-91.
(2)Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here.
(3) Frasca D., Dahyot-Fizelier C., Catherine K., Levrat Q., Debaene B., Mimoz O. "Accuracy of a Continuous Noninvasive Hemoglobin Monitor in Intensive Care Unit Patients." Crit Care Med. 2011 Oct;39(10):2277-82. Available online here.
(4) Cannesson M., Desebbe O., Rosamel P., Delannoy B., Robin J., Bastien O., Lehot J.J. "Pleth Variability Index to Monitor the Respiratory Variations in the Pulse Oximeter Plethysmographic Waveform Amplitude and Predict Fluid Responsiveness in the Operating Theatre."Br J Anaesth. 2008 Aug;101(2):200-6. Available online here.
About Kennedy Health System
The Kennedy Health System is an integrated healthcare delivery system providing a full continuum of healthcare services, ranging from acute-care hospitals to a broad spectrum of outpatient and wellness programs. A multi-site healthcare provider, Kennedy serves the residents of Camden, Burlington and Gloucester counties. Our mission - to enhance the health status of the communities it serves - is further expanded through our educational commitment and affiliation with the University of Medicine and Dentistry of New Jersey. Kennedy provides the largest non-public physician training program in the state of New Jersey. Kennedy Health System has three hospital campuses in Southern New Jersey: Cherry Hill, Stratford and Washington Township. Please visit www.kennedyhealth.org.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient carehelping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOCTM), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic MonitoringTM, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and acquired PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb), PVI, and acoustic respiration rate (RRa) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Phone: (949) 297-7434
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.